AI assistant
Sending…
Processa Pharmaceuticals, Inc. — Director's Dealing 2023
Feb 10, 2023
35172_dirs_2023-02-10_75d552ad-02ed-4db1-ab06-8a275f66815c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Processa Pharmaceuticals, Inc. (PCSA)
CIK: 0001533743
Period of Report: 2023-02-09
Reporting Person: Stanker James H (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-02-09 | Common Stock | A | 12500 | $.80 | Acquired | 61750 | Direct |
More from Processa Pharmaceuticals, Inc.
Regulatory Filings
2026
Feb 19
Director's Dealing
2026
Feb 4
Director's Dealing
2026
Feb 4
Director's Dealing
2026
Feb 4
Director's Dealing
2026
Feb 4
Regulatory Filings
2026
Jan 7
Regulatory Filings
2025
Dec 15
Major Shareholding Notification
2025
Nov 7
Interim / Quarterly Report
2025
Nov 6
Major Shareholding Notification
2025
Oct 15